Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Larder

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
AIDS (London, England)|January 31, 2002
Mechanisms of HIV-1 drug resistanceB Larder
The EMBO Journal|October 1, 1987
AIDS virus reverse transcriptase defined by high level expression in Escherichia coliB Larder, D Purifoy, K Powell, et al.
HIV Clinical Trials|December 14, 2001
Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapyT Middleton, D Smith, B Larder, et al.
Nucleosides, Nucleotides & Nucleic Acids|September 21, 2001
Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samplesM D Miller, N A Margot, K Hertogs, et al.
The Journal of Infectious Diseases|February 1, 1994
Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patientsF Luque, A Caruz, J A Pineda, et al.
The Journal of Infection|June 22, 2002
Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991P J Easterbrook, K Hertogs, A Waters, et al.
Science Advances|December 6, 2019
Fast nonadiabatic dynamics of many-body quantum systemsB Larder, D O Gericke, S Richardson, et al.
AIDS Research and Human Retroviruses|October 27, 2001
Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapyL Ross, Q Liao, H Gao, et al.
Science (New York, N.Y.)|November 24, 1995
Cytotoxic T lymphocyte lysis inhibited by viable HIV mutantsU C Meier, P Klenerman, P Griffin, et al.
The Journal of Infectious Diseases|March 18, 2000
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative GroupP R Harrigan, C Stone, P Griffin, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
AIDS (London, England)|January 31, 2002
Mechanisms of HIV-1 drug resistanceB Larder
The EMBO Journal|October 1, 1987
AIDS virus reverse transcriptase defined by high level expression in Escherichia coliB Larder, D Purifoy, K Powell, et al.
HIV Clinical Trials|December 14, 2001
Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapyT Middleton, D Smith, B Larder, et al.
Nucleosides, Nucleotides & Nucleic Acids|September 21, 2001
Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samplesM D Miller, N A Margot, K Hertogs, et al.
The Journal of Infectious Diseases|February 1, 1994
Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patientsF Luque, A Caruz, J A Pineda, et al.
The Journal of Infection|June 22, 2002
Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991P J Easterbrook, K Hertogs, A Waters, et al.
Science Advances|December 6, 2019
Fast nonadiabatic dynamics of many-body quantum systemsB Larder, D O Gericke, S Richardson, et al.
AIDS Research and Human Retroviruses|October 27, 2001
Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapyL Ross, Q Liao, H Gao, et al.
Science (New York, N.Y.)|November 24, 1995
Cytotoxic T lymphocyte lysis inhibited by viable HIV mutantsU C Meier, P Klenerman, P Griffin, et al.
The Journal of Infectious Diseases|March 18, 2000
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative GroupP R Harrigan, C Stone, P Griffin, et al.
Pageof 4